ACCELERATED PUBLICATION
A Novel Glucokinase Regulator in Pancreatic beta  Cells

PRECURSOR OF PROPIONYL-CoA CARBOXYLASE beta  SUBUNIT INTERACTS WITH GLUCOKINASE AND AUGMENTS ITS ACTIVITY*

Akihiko ShiraishiDagger §, Yuichiro YamadaDagger , Yoshiyuki TsuuraDagger , Shimpei FijimotoDagger , Katsushi TsukiyamaDagger , Eri MukaiDagger , Yukiyasu Toyoda, Ichitomo Miwa, and Yutaka SeinoDagger

From the Dagger  Department of Metabolism and Clinical Nutrition, Graduate School of Medicine, Kyoto University, Sakyoku, Kyoto 606-8507 and the  Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Tempaku-ku, Nagoya 468-8503, Japan

Received for publication, August 7, 2000, and in revised form, November 11, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A glucokinase regulatory protein has been reported to exist in the liver, which suppresses enzyme activity in a complex with fructose 6-phosphate, whereas no corresponding protein has been found in pancreatic beta  cells. To search for such a protein in pancreatic beta  cells, we screened for a cDNA library of the HIT-T15 cell line with the cDNA of glucokinase from rat islet by the yeast two hybrid system. We detected a cDNA encoding the precursor of propionyl-CoA carboxylase beta  subunit (pbeta PCCase), and glutathione S-transferase pull-down assay illustrated that pbeta PCCase interacted with recombinant rat islet glucokinase and with glucokinase in rat liver and islet extracts. Functional analysis indicated that pbeta PCCase decreased the Km value of recombinant islet glucokinase for glucose by 18% and increased Vmax value by 23%. We concluded that pbeta PCCase might be a novel activator of glucokinase in pancreatic beta  cells.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Glucose phosphorylation is known to be the rate-limiting step in glycolysis of pancreatic beta  cells (1). This step is catalyzed by hexokinase through a low Km pathway and by glucokinase through a high Km pathway (2, 3). Glucokinase predominantly regulates intracellular glucose metabolism when ambient glucose concentration is increased (4), and the reduced activity of this enzyme has been reported to decrease glucose-induced insulin release (5). Glucokinase is also expressed in the liver, which is another regulatory center of glucose homeostasis. Van Schaftingen et al. (6) have reported that the rat liver contains a regulatory protein that binds to glucokinase, and the activity of glucokinase coupled to this protein is thought to be mediated by competitive binding of fructose 6-phosphate and fructose 1-phosphate in the liver (6, 7). Thus, this feedback regulation may affect the balance of glycolysis and gluconeogenesis. There have also been attempts to find a corresponding protein in pancreatic islets (8). Fructose 1-phosphate converted from fructose was reported to enhance glucokinase activity in vitro (9), and a greater increase in glucokinase activity has been reported in extracts from islets overexpressing glucokinase without an increase of glucose utilization (10). These reports suggested the existence of a factor capable of regulating glucokinase activity or its affinity for glucose under physiological intracellular conditions, although as yet, no direct evidence for such a molecule has been reported. To clarify whether a glucokinase regulatory protein is present in pancreatic islets, we screened for a cDNA library of the HIT-T15 cell line with the cDNA of glucokinase from rat pancreatic beta  cells using the yeast two hybrid system and found a novel binding regulator for glucokinase.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

cDNA Cloning-- Rat pancreatic islet glucokinase full-length cDNA was amplified by polymerase chain reaction (PCR)1 using pancreatic beta  cell glucokinase-specific oligonucleotides (11). This cDNA was subcloned into the following two types of plasmids: pBTM116, the "bait" for yeast two hybrid screen (pBTM116-GK), and pGEX4T-1 (Amersham Pharmacia Biotech) to produce glutathione S-transferase (GST)-fused glucokinase (GST-GK). Full-length cDNA of precursor of propionyl-CoA carboxylase beta  subunit (pbeta PCCase) in pancreatic islet was also amplified from rat pancreatic islets cDNA by PCR using the oligonucleotides for rat liver pbeta PCCase (12).

Recombinant Protein-- Rat pancreatic islet glucokinase and pbeta PCCase were subcloned into pGEX4T-1 and transformed into Escherichia coli strain M15. Following induction of protein expression with isopropyl thio-beta -D-galactosidase, the GST fusion proteins were purified according to the manufacturer's instructions (Amersham Pharmacia Biotech) (13). The produced protein was dissolved in 50 mM Tris-HCl, pH 8.0. Recombinant glucokinase without GST tag (rGK) was made by thrombin cleavage according to the manufacturer's instruction.

Screening for the cDNA Encoding a Protein with Affinity for Rat Islet Glucokinase by the Yeast Two Hybrid System-- Yeast two hybrid screening was performed as described previously (14). The bait plasmid was pBTM116-GK, in which rat pancreatic beta  cell glucokinase was fused to the LexA DNA-binding domain. The yeast strain L40 (MATa trp1 leu2 his3 LYS2::lexA-HIS3 URA3::lexA-LacZ) was transformed with pBTM116-GK using the lithium acetate method (15). Strain L40 carrying pBTM116-GK was transformed with a HIT-T15 (hamster pancreatic beta  cell line (16)) cell cDNA library. Approximately 1.0 × 106 transformants were screened for growth on Yc plate medium (2% glucose, 0.5% ammonium sulfate, 1% succinic acid, and 0.12% yeast nitrogen base) containing 0.5 mM 3-amino-1,2,4-triazole but lacking tryptophan, histidine, uracil, and leucine. His+ colonies were then placed on paper filters and stained with 5-bromo-4-chloro-3-indolyl-beta -D-galactopyranoside for beta -galactosidase activity as described (15). Two His+ and LacZ+ clones were obtained with this screening. The plasmids were transformed to E. coli and isolated.

Preparation of Rat Pancreatic Islet and Liver Extract-- Pancreatic islets were isolated from male Wistar rats by collagenase digestion as described previously (17) and were then sonicated in RIPA (150 mM NaCl, 1.0% Nonidet P-40, 50 mM Tris-HCl, pH 8.0). The homogenate was centrifuged at 10,000 × g for 15 min at 4 °C, and the supernatant was collected as the islet extract. Rat liver tissue was also homogenized in RIPA, and the supernatant was collected after centrifugation at 10,000 × g for 15 min at 4 °C as liver extract.

Preparation of Islet Cellular Fractions-- Sucrose gradient fractionation was performed for collected islets by the previously described method (18). Islets in the 0.25 M sucrose were homogenized in a Potter-Elvehjem homogenizer with 6 strokes of a close-fitting Teflon pestle. The mixture was centrifuged for 10 min at 600 × g. The pellet was further purified by the method of Blobel-Potter to obtain the purified nuclear fraction (19). The supernatant was centrifuged for 10 min at 8,000 × g. The pellet was collected as the mitochondrial fraction, and the supernatant was centrifuged for 60 min at 105,000 × g. The resultant pellet was the microsomal fraction, and the supernatant was the cytosolic fraction. Each subcellular fraction was analyzed by SDS-PAGE and Western blotting with anti-pbeta PCCase serum as described previously (13). The anti-pbeta PCCase serum was made from a rabbit immuned with GST-pbeta PCCase.

In Vitro Protein Interaction Assays-- GST pull-down assay was performed as described previously (13). Each assay contained GST fusion protein immobilized on glutathione-Sepharose beads (Amersham Pharmacia Biotech). Briefly, samples containing glucokinase (5 µg of rGK, rat pancreatic islet extract, or liver extract) were incubated with 3 µg of GST (molecular mass, 27 kDa) or 9 of µg GST-pbeta PCCase (molecular mass, 89 kDa) or 8 µg of GST-GK (molecular mass, 79 kDa) in binding buffer (20 mM Tris-HCl, pH 7.6, 0.1 mM EDTA, 20% glycerol, 300 mM KCl, 0.1% Nonidet P-40, 0.5 mM phenylmethylsulfonyl fluoride, 2 mM MgCl2, and 5 mM 2-mercaptoethanol) for 1 h at 4 °C. After incubation, the beads were washed five times with binding buffer (10-fold volume of beads) and resuspended in elution buffer (binding buffer containing 10 mM reduced glutathione). The bound proteins were resolved by 10% SDS-PAGE and visualized by Western blotting with rabbit anti-glucokinase antibody or anti-pbeta PCCase serum as described previously (13, 20).

Assay for Glucokinase Activity-- Glucokinase enzyme activity was measured by a fluorometric assay according to the method reported previously (21). Glucokinase activity was measured as the fluorescence of NADPH at excitation and emission wavelengths of 340 and 450 nm, respectively. The reaction was performed in a solution consisting of 50 mM HEPES-NaOH, pH 7.4, 100 mM KCl, 8 mM MgCl2, 0.5 mM NADP, 1 mM dithiothreitol, 1 unit/ml of glucose 6-phosphate dehydrogenase, ATP at various concentrations, and 0.2 µg/ml of GST-GK supplemented with various concentrations of glucose at 37 °C for half an hour and was stopped by addition of stop solution (300 mM NaH2PO4, 0.46 mM sodium dodecylsulfate, pH 8.0). Reagent blanks were incubated in the absence of ATP and were subtracted from the total fluorescence of the corresponding complete reaction mixtures. The Km, Vmax, and Hill coefficient were determined by the nonlinear least squares routine to fit the Hill equation using Sigma Plot (1, 9).

Statistical Analysis-- All data are expressed as means ± S.E., with n values being the number of experiments performed. Statistical significance was determined by paired Student's t test.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The yeast two hybrid system was used to identify cDNAs in the HIT-T15 cell cDNA library encoding the regulatory protein using the bait plasmid pBTM116-GK. The resultant cDNA insert was isolated by nutritional selection and beta -galactosidase activity and was shown to be 68% of the rat liver pbeta PCCase gene by sequence analysis. The full-length cDNA of pbeta PCCase was obtained from rat pancreatic islet cDNA by a PCR-based method. The specificity of the interaction between pancreatic islet glucokinase and pancreatic islet pbeta PCCase was tested in vitro. The GST-fused pbeta PCCase (GST-pbeta PCCase) could bind to rGK and glucokinase in cellular extracts of rat pancreatic islets and liver (Fig. 1). Furthermore, the GST-fused glucokinase (GST-GK) could bind to pbeta PCCase in cellular extracts of rat pancreatic islets (Fig. 1D).



View larger version (55K):
[in this window]
[in a new window]
 
Fig. 1.   Interaction of pbeta PCCase with GK. A, interaction of GST-pbeta PCCase with recombinant GK. B, interaction of GST-pbeta PCCase with cellular extract of pancreatic islets. C, interaction of GST-pbeta PCCase with cellular extract of liver. D, interaction of GST-GK with cellular extract of pancreatic islets. GST-pbeta PCCase interacted with GK, and GST-GK interacted with pbeta PCCase in vitro. GST or GST-pbeta PCCase, immobilized on glutathione beads, was incubated with recombinant GK, rat pancreatic islet, or liver cellular extract. GST-GK immobilized on glutathione beads was also incubated with islet extract. Bound proteins were detected with anti-GK antibodies or anti-pbeta PCCase serum.

Western blotting was performed to confirm the subcellular localization of pbeta PCCase in islets. pbeta PCCase was shown to be present in the mitochondrial fraction and cytosolic fraction, but it was not detected in the microsomal or nuclear fractions (Fig. 2).



View larger version (57K):
[in this window]
[in a new window]
 
Fig. 2.   pbeta PCCase in various islet cell fractions. Western blotting with anti-pbeta PCCase serum is shown. pbeta PCCase was visualized in the cytosolic fraction and mitochondrial fraction. Each lane contained 1 µg of protein.

Next, the effects of GST-pbeta PCCase on glucokinase activity were investigated. When 25 µg/ml GST-pbeta PCCase was added, GST-GK activity was significantly higher than that in controls within the range of 3 to 50 mM glucose (Fig. 3A), whereas the GST tag alone did not show any effect on GST-GK activity (data not shown). GST-pbeta PCCase had no activity of hexokinase or glucokinase. The glucokinase inhibitor mannoheptulose at 20 mM suppressed the activity of GST-GK by 67 or 60% in the presence or absence of pbeta PCCase, respectively, when the activity was assayed in the presence of 10 mM glucose and 5 mM ATP. The Vmax value of GST-GK for glucose was increased by about 23%, and the Km value was reduced by 18% when GST-pbeta PCCase was added (Table I). The Hill number was 1.8 in the presence of GST-pbeta PCCase, which was not significantly different from the value of 1.7 in controls (Table I). Furthermore, the Km value of GST-GK for ATP was not affected by addition of GST-pbeta PCCase (see Fig. 3B and Table I). The activity of GST-GK was increased in a GST-pbeta PCCase concentration-dependent manner (Fig. 3C). In the previous reports, palmitoyl-CoA has been shown to suppress glucokinase activity at higher concentrations beyond physiological ones (22-24). We tested the effects of pbeta PCCase on glucokinase activity in the presence or absence of palmitoyl-CoA and propionyl-CoA. The activating effect of GST-pbeta PCCase was not influenced by the presence of 3 µM palmitoyl-CoA and 3 µM propionyl-CoA (data not shown).



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of pbeta PCCase on GK activity. A, reaction velocity of GST-GK (closed circles) or GST-GK + 25 mg/ml GST-pbeta PCCase (open circles) with glucose concentrations from 0.05 to 50 mM at 5 mM ATP (n = 5). B, reaction velocity of GST-GK (closed circles) or GST-GK + GST-pbeta PCCase (open circles) with ATP concentrations from 0.01 to 10 mM at 5 mM glucose (n = 4). C, reaction velocity of GK with various concentrations of pbeta PCCase (up to 30 µg/ml) at 10 mM glucose and 5 mM ATP (n = 5). Values shown are means ± S.E. from four or five independent experiments. * indicates p < 0.01 (or 0.05) versus each control value.


                              
View this table:
[in this window]
[in a new window]
 
Table I
Kinetic parameters of GST-GK activity in the presence or absence of GST-pbeta PCCase
h, Hill coefficient number; NS, not significant. The data are expressed as means ± S.E. Km, Vmax, and h were calculated from six independent experiments, and Km(ATP) was calculated from four independent experiments.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study, we found that pbeta PCCase, which is present in the cytosolic compartment (25-27), unexpectedly interacted with pancreatic islet glucokinase and activated its enzyme activity with increased Vmax and decreased Km values for glucose.

Liver and pancreatic beta  cells play crucial roles in glucose homeostasis, but they have distinctive functions (28). In the liver, in response to changes in plasma glucose concentration, hepatic glucose uptake and glucose output are alternatively increased to maintain the plasma glucose concentration. Accordingly, an abrupt alteration of ambient glucose concentration might require a negative feedback loop for glucokinase activity by binding of a regulatory protein coupled to fructose 6-phospate (6, 29). On the other hand, pancreatic beta  cells secrete insulin in response to increasing glucose concentration (4). A glucose-induced insulin secretion is subject to intracellular glucose metabolism, and in beta  cells glucose metabolism unidirectionally flows toward the direction of ATP production with the metabolic characteristic of development of a glycerol phosphate shuttle (30), lack of fructose-bisphosphatase (31), and a low activity of lactate dehydrogenase (32). However, a positive regulator of glucokinase, which has the lowest activity among all the glycolytic enzymes, had not been found in pancreatic beta  cells. In the present study, we demonstrated that pbeta PCCase increased Vmax of glucokinase for glucose and reduced Km. Such regulation may enable maximal enhancement of glucose metabolism in the range of physiological ambient glucose concentrations.

pbeta PCCase is a precursor of the beta  subunit in propionyl-CoA carboxylase (PCCase), a biotin-dependent enzyme that is present in the matrix of mitochondria (25-27). pbeta PCCase protein (61.5 kDa) is known to be synthesized on cytoplasmic polyribosomes and transferred to the mitochondria via a specific transporter. After arrival at the mitochondrial matrix, pbeta PCCase is processed to mature beta  subunit of propionyl-CoA carboxylase protein (54 kDa) by a Zn2+-dependent proteolytic component in the matrix (27). Thus, pbeta PCCase could exist in the cytoplasmic compartment. The importance of the regulation of glucokinase activity by pbeta PCCase remains to be determined. Pancreatic beta  cells are continuously exposed to not only glucose but also fatty acids, which are known to affect glucose-induced insulin secretion (33, 34). Palmitate and oleate are strong potentiators of glucose-induced insulin release (35, 36), and Liu et al. (33) reported that glucose utilization examined using [2H]glucose was augmented accompanied by a decrease in the level of glucose 6-phosphate in islets cultured with oleate. These findings seemed to be consistent with the hypothesis that a precursor of PCCase beta  subunit, which exists in the cytosolic compartment and is known to become as functional as PCCase in fatty acid metabolism in the mitochondrial matrix (36, 37), enhances the glycolytic pathway by up-regulating glucokinase activity. This hypothesis might be applicable to the glucose metabolism in the liver. In addition, pbeta PCCase might contribute to the localization of glucokinase by transporting the coupled enzyme in the liver and pancreatic beta  cells.

In conclusion, pbeta PCCase has been shown to be a novel activator of glucokinase. Unlike the binding regulatory protein in the liver (7, 6), pbeta PCCase alters the Km and Vmax values of glucokinase for glucose, resulting in enhanced enzyme activity in islets. Because glucokinase is a rate-limiting enzyme (28), pbeta PCCase may be directly involved in the regulation of glucose metabolism and glucose-induced insulin secretion in pancreatic islets.


    ACKNOWLEDGEMENTS

We thank Susumu Seino of Chiba University Graduate School of Medicine for arranging the yeast two hybrid screening system.


    FOOTNOTES

* This study was supported in part by grants-in-aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan, Grant-in-Aid for Creative Basic Research 10NP0201 from the Ministry of Education, Science, Sports and Culture of Japan, and grants from the Research for the Future Program of the Japan Society for the Promotion of Science (JSPS-RFTF97I00201).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Dept. of Metabolism and Clinical Nutrition, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyoku, Kyoto 606-8507, Japan. Tel.: 81-75-751-3560; Fax: 81-75-751-4244; E-mail: siraisi@metab.kuhp. kyoto-u.ac.jp.

Published, JBC Papers in Press, November 20, 2000, DOI 10.1074/jbc.C000530200


    ABBREVIATIONS

The abbreviations used are: PCR, polymerase chain reaction; GST, glutathione S-transferase; GK, glucokinase; pbeta PCCase, precursor of propionyl-CoA carboxylase beta  subunit; r, recombinant; PCCase, propionyl-CoA carboxylase.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Matschinsky, F. M., Glaser, B., and Magnuson, M. A. (1998) Diabetes 47, 307-315[Abstract]
2. Xu, L. Z., Harrison, R. W., Weber, I. T., and Pilkis, S. J. (1995) J. Biol. Chem. 270, 9939-9946[Abstract/Free Full Text]
3. Schuit, F., Moens, K., Heimberg, H., and Pipeleers, D. (1999) J. Biol. Chem. 274, 32803-32809[Abstract/Free Full Text]
4. Matschinsky, F. M., and Collins, H. W. (1997) Chem. Biol. 4, 249-257[Medline] [Order article via Infotrieve]
5. Wang, H., and Iynedjian, P. B. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4372-4377[Abstract/Free Full Text]
6. van Schaftingen, E., Detheux, M., and da Cunha Veiga, M. (1994) FASEB J. 8, 414-419[Abstract/Free Full Text]
7. Vandercammen, A., and van Schaftingen, E. (1990) Eur. J. Biochem. 191, 483-489[Abstract]
8. Tiedge, M., Steffeck, H., Elsner, M., and Lenzen, S. (1999) Diabetes 48, 514-523[Abstract]
9. Malaisse, W. J., Malaisse-Lagae, F., Davies, D. R., Vandercammen, A., and van Schaftingen, E. (1990) Eur. J. Biochem. 190, 539-545[Abstract]
10. Becker, T. C., Noel, R. J., Johnson, J. H., Lynch, R. M., Hirose, H., Tokuyama, Y., Bell, G. I., and Newgard, C. B. (1996) J. Biol. Chem. 271, 390-394[Abstract/Free Full Text]
11. Magnuson, M. A., and Shelton, K. D. (1989) J. Biol. Chem. 264, 15936-15942[Abstract/Free Full Text]
12. Kraus, J. P., Firgaira, F., Novotny, J., Kalousek, F., Williams, K. R., Williamson, C., Ohura, T., and Rosenberg, L. E. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 8049-8053[Abstract]
13. Inada, A., Someya, Y., Yamada, Y., Ihara, Y., Kubota, A., Ban, N., Watanabe, R., Tsuda, K., and Seino, Y. (1999) J. Biol. Chem. 274, 21095-21103[Abstract/Free Full Text]
14. Kotake, K., Ozaki, N., Mizuta, M., Sekiya, S., Inagaki, N., and Seino, S. (1997) J. Biol. Chem. 272, 29407-29410[Abstract/Free Full Text]
15. Vojtek, A. B., Hollenberg, S. M., and Cooper, J. A. (1993) Cell 74, 205-214[Medline] [Order article via Infotrieve]
16. Ashcroft, S. J., Hammonds, P., and Harrison, D. E. (1986) Diabetologia 29, 727-733[Medline] [Order article via Infotrieve]
17. Kajikawa, M., Ishida, H., Fujimoto, S., Mukai, E., Nishimura, M., Fujita, J., Tsuura, Y., Okamoto, Y., Norman, A. W., and Seino, Y. (1999) Endocrinology 140, 4706-4712[Abstract/Free Full Text]
18. Hogebon, G. H. (1955) Methods Enzymol. 1, 16-19
19. Blobel, G., and Van Potter, R. (1966) Science 154, 1662-1664[Medline] [Order article via Infotrieve]
20. Toyoda, Y., Miwa, I., Kamiyama, M., Ogiso, S., Okuda, J., and Nonogaki, T. (1995) FEBS Lett. 359, 81-84[CrossRef][Medline] [Order article via Infotrieve]
21. Miwa, I., Mita, Y., Murata, T., Okuda, J., Sugiura, M., Hamada, Y., and Chiba, T. (1995) Enzyme Protein 48, 135-142
22. Tippett, P. S., and Neet, K. E. (1982) J. Biol. Chem. 257, 12839-12845[Free Full Text]
23. Tippett, P. S., and Neet, K. E. (1982) J. Biol. Chem. 257, 12846-12852[Free Full Text]
24. Printz, R. L., Magnuson, M. A., and Granner, D. K. (1993) Annu. Rev. Nutr. 13, 463-496[CrossRef][Medline] [Order article via Infotrieve]
25. Browner, M. F., Taroni, F., Sztul, E., and Rosenberg, L. E. (1989) J. Biol. Chem. 264, 12680-12685[Abstract/Free Full Text]
26. Moss, J., and Lane, M. D. (1971) Adv. Enzymol. 35, 321-342[Medline] [Order article via Infotrieve]
27. Kraus, J. P., Kalousek, F., and Rosenberg, L. E. (1983) J. Biol. Chem. 258, 7245-7248[Abstract/Free Full Text]
28. Matschinsky, F. M. (1990) Diabetes 39, 647-652[Abstract]
29. Siota, C., Coffey, J., Grimsby, J., Grippo, J. F., and Magnuson, M. A. (1999) J. Biol. Chem. 274, 37125-37130[Abstract/Free Full Text]
30. MacDonald, M. J. (1981) J. Biol. Chem. 256, 8287-8290[Abstract/Free Full Text]
31. Sener, A., and Malaisse, W. J. (1978) Diabetes Metab. 4, 127-133
32. Sekine, N., Cirulli, V., Regazzi, R., Brown, L. J., Gine, E., Tamarit-Rodriguez, J., Girotti, M., Marie, S., MacDonald, M. J., and Wollheim, C. B. (1994) J. Biol. Chem. 269, 4895-4902[Abstract/Free Full Text]
33. Liu, Y. Q., Tornheim, K., and Leahy, J. L. (1998) J. Clin. Invest. 101, 1870-1875[Abstract/Free Full Text]
34. Unger, R. H. (1995) Diabetes 44, 863-870[Abstract]
35. Hosokawa, H., Corkey, B. E., and Leahy, J. L. (1997) Diabetologia 40, 392-397[CrossRef][Medline] [Order article via Infotrieve]
36. Warnotte, C., Gilon, P., Nenquin, M., and Henquin, J. C. (1994) Diabetes 43, 703-711[Abstract]
37. Scholte, H. R. (1969) Biochim. Biophys. Acta 178, 137-144[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.